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Abstract
Background: Pancreatic cancer is the fourth leading cause of cancer-related death. While surgical resection remains
the foundation for potentially curative treatment, survival benefit is achieved with adjuvant oncological treatment.
Thus, completion of multimodality treatment (surgical resection and (neo)adjuvant chemotherapy) to all patients
and early treatment of micrometastatic disease is the ideal goal. NorPACT–1 aims to test the hypothesis that overall
mortality at one year after allocation of treatment can be reduced with neoadjuvant chemotherapy in surgically treated
patients with resectable pancreatic cancer.
Methods/Design: The NorPACT– 1 is a multicentre, randomized controlled phase III trial organized by the Norwegian
Gastrointestinal Cancer Group for Hepato-Pancreato-Biliary cancer. Patients with resectable adenocarcinoma of the
pancreatic head are randomized to receive either surgery first (Group 1: SF/control) or neoadjuvant chemotherapy
(Group 2: NT/intervention) with four cycles FOLFIRINOX followed by resection. Both groups receive adjuvant chemotherapy
with gemicitabine and capecitabine (six cycles in Group 1, four cycles in Group 2). In total 90 patients will be randomized in
all the five Norwegian university hospitals performing pancreatic surgery. Primary endpoint is overall mortality at one year
following commencement of treatment for those who ultimately undergo resection. Secondary endpoints are
overall survival after date of randomization (intention to treat), overall survival after resection, disease-free survival,
histopathological response, complication rates after surgery, feasibility of neoadjuvant and adjuvant chemotherapy,
completion rates of all parts of multimodal treatment, and quality-of-life. Bolt-on to the study is a translational research
program that aims at identifying factors that are predictive of response to NT, the risk of distant cancer spread, and
patient outcome.
Discussion: NorPACT– 1 is designed to investigate the additional benefit of NT compared to standard treatment only
(surgery + adjuvant chemotherapy) for resectable cancer of the pancreatic head to decrease early mortality (within one
year) in resected patients.
Trial registration: Trial open for accrual 01.02.2017.
ClinicalTrials.gov Identifier: NCT02919787. Date of registration: September 14, 2016.
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Background
Pancreatic cancer is the fourth leading cause of cancer-
related death in Europe and the United States [1, 2]. Surgi-
cal resection remains the only potentially curative treat-
ment. However, the median survival of patients undergoing
pancreatic resection alone is 16–23 months, with a 5-year
overall survival between 10 and 20% [3–6]. Adjuvant
chemotherapy improves the median and 5-year overall sur-
vival [4, 7]. Thus, completion of multimodality treatment is
the ideal goal and standard of care for treatment of pancre-
atic ductal adenocarcinoma (PDAC). It is well known that
initiation and completion of adjuvant chemotherapy can be
precluded by perioperative complications [6, 8, 9]. Compli-
cations following pancreatoduodenectomy are encountered
in 40–50% of patients, with a perioperative mortality rate
of 2–4% [10–12]. The technical complexity of the oper-
ation and the frailty and co-morbidity of the patient popu-
lation contribute to the high rate of complications. A
significant proportion of patients undergoing pancreatec-
tomy for PDAC develops recurrent disease within 2 years
after surgery, and about 20% of the patients have early dis-
ease progression within six months after resection [6, 13].
Likely, patients with early distant recurrence had occult
metastasis at the time of operation, and may thus have
been inadequately selected for surgery. However, useful
clinical criteria for accurate prediction of patients suspect-
able to suffer an early distant or loco-regional recurrence
are not available.
Currently, the surgery-first (SF) strategy is the most uni-
versally accepted approach (and the standard of care in
Norway) to the treatment of resectable PDAC. Still, the
optimal sequence of surgery and chemotherapy remains
unclear [14, 15]. In three European well-designed random-
ized controlled trials that accrued patients with good per-
formance status and following stringent tumour biology
criteria (such as low CA 19–9 levels), the initiation rate of
adjuvant therapy was 83–90% [4, 5, 7]. However, only 50–
62% completed multimodal treatment in these highly se-
lected patients. Given the significant survival benefit of ad-
juvant chemotherapy, the completion rates reported in the
literature remain too low. Some centres advocate neoadju-
vant chemotherapy (NT) as an alternative to the SF ap-
proach [16, 17]. Proponents of the NT strategy suggest
that the negative impact of early cancer progression and
postoperative complications upon completion of multi-
modality treatment is reduced by delivery of NT prior to
pancreatoduodenectomy [8]. However, the scheduled re-
section has to be cancelled in up to 20% of patients receiv-
ing NT due to early metastases, reduced performance-
status or comorbidities during NT, but very rarely due to
local tumour progression alone [17]. Chemotherapy
employed upfront (before surgery) in patients with re-
sectable pancreatic cancer could potentially increase the
proportion of patients who eventually received both
treatment modalities, and thus, may benefit from a com-
bined effect.
To date, there are no prospective data proving the su-
periority of one sequence strategy over the other. Recent
studies have shown promising results using NT with FOL-
FIRINOX for locally advanced and borderline resectable
pancreatic cancer, and for the palliative treatment of meta-
static pancreatic cancer [18, 19]. Available data on early
distant recurrence after pancreatoduodenectomy or dur-
ing NT support the concept of pancreatic cancer as a sys-
temic disease, even in early-stage settings [20]. Currently,
by comparing multi-agent regimens to single-agent ap-
proaches efforts are made to bring systemic therapy up-
front to study the effect of aggressive chemotherapy
regimens in well-designed clinical trials. To circumvent
patient selection bias, only a randomized comparison can
objectively show benefit of one strategy over the other.
The purpose of this study is to further investigate the
benefit of adding NT in comparison to standard treatment
only for resectable cancer of the pancreatic head (surgery
followed by adjuvant chemotherapy).
Methods/Design
Design
The Norwegian Pancreatic Cancer Trial (NorPACT) - 1 is
a multicentre, randomized controlled phase III trial orga-
nized by the Norwegian Gastrointestinal Cancer Group
(NGICG) for Hepato-Pancreato-Biliary (HPB) cancer. Eli-
gible patients are randomized in non-equal groups (3:2) to
either receive NT followed by resection or standard treat-
ment ((pancreatoduodenectomy) followed by adjuvant
chemotherapy) (Fig. 1). The aim of this study is to evalu-
ate the additional benefit of NT to the standard treatment
(surgery + adjuvant chemotherapy) to decrease early mor-
tality (within one year) in resected patients with resectable
cancer of the pancreatic head.
Primary end points:
□ overall mortality at one year following commencement
of treatment (NT or SF) for those patients who undergo
resection (i.e. only resected patients are included in the
analysis)
Secondary end points:
□ overall survival after date of randomization (intention
to treat)
□ overall survival following resection
□ overall survival after 3 and 5 years
□ disease-free survival
□ histopathological tumour stage ((y)pTN), R0 rate,
grade of tumour regression
Labori et al. BMC Surgery  (2017) 17:94 Page 2 of 7
□ complication rates after surgery (30 and 90 days,
Dindo-Clavien and International Study Group of
Pancreatic Surgery (ISGPS) classification systems)
[21–25]
□ feasibility of neoadjuvant and adjuvant
chemotherapy (Common Terminology Criteria
for Adverse Events, grade 3–5, dose reduction,
dose delay)
□ completion rates of all parts of multimodal
treatment
□ quality of life (EORTC QLQ-30)
□ performance status (ECOG) compared to baseline
values
□ exploratory translational research
Study population
Patients meeting the National Comprehensive Cancer
Network criteria for resectable pancreatic adenocarcin-
oma in the pancreatic head are eligible [14]. This im-
plies: 1) no tumour contact with the superior mesenteric
vein or portal vein or ≤180 ° contact without vein con-
tour irregularity, 2) no arterial tumour contact (coeliac
axis, common hepatic artery or superior mesenteric ar-
tery), 3) no distant metastasis.
Inclusion criteria (all of the following):
□ resectable ductal adenocarcinoma of the
pancreatic head
Fig. 1 Flowchart of the Norwegian pancreatic cancer trial-1
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□ T1–3, Nx, M0 (UICC 7th edition, 2010)
□ cytological or histological confirmation or strong
suspicion of adenocarcinoma
□ age > 18 year and considered fit for major surgery
□ written informed consent
□ considered able to receive the study-specific
chemotherapy
Exclusion criteria (one or more of the following):
□ co-morbidity precluding pancreatoduodenectomy
□ histological type other than ductal adenocarcinoma
□ chronic neuropathy ≥ grade 2
□ World Health Organization performance score > 2
□ granulocyte count <1500 per cubic millimetre
□ platelet count <100,000 per cubic millimetre
□ serum creatinine >1.5 UNL (upper limit normal range)
□ albumin <2.5 g/dl
□ female patients in child-bearing age not using
adequate contraception, pregnant or lactating women
□ mental or physical disorders that could interfere
with treatment or the provision of informed consent
□ other malignancy within the past 5 years, except
curatively treated non-melanomatous skin or non-
invasive cervical cancer
□ percutaneous tumour biopsy
□ any reason why, in the opinion of the investigator,
the patient should not participate
Locations
Surgery for malignancies of the pancreatic head is cur-
rently performed only at five university hospitals in
Norway. These departments have all agreed to partici-
pate in this trial.
Participating centres are: Oslo University Hospital,
Haukeland University Hospital (Bergen), Stavanger Uni-
versity Hospital, St. Olav University Hospital (Trondheim),
and the University Hospital Northern Norway in Tromsø.
Each centre has a main investigator who liaises with the
central study board.
Time frame
In Norway, annually 60–70 patients are expected to have
primary resectable pancreatic adenocarcinoma in the
pancreatic head. Patients will be recruited into the trial
between 1st of January 2017 and 31st of December 2019
(36 months).
Randomization
After the patient has given oral and written consent,
computer-generated randomization will be performed.
Randomization is to either
□ GROUP 1 (control): Surgery First
□ GROUP 2 (intervention): Neoadjuvant Chemotherapy
There will be an overweight of Group 2 allocations by
a ratio of 3:2 to ensure equal groups at primary endpoint
(cfr. below). Randomization is stratified for each centre
and will be generated in blocks with unknown and vary-
ing size (4–6 patients per block) to ensure that groups
are balanced at all centres, irrespective of the final num-
ber of patients recruited.
Sample-size calculation
Based on available data, we assume a one-year overall
mortality rate of 25% in the SF arm (Group 1) [5, 6, 26].
Based on highly selected patient series, a suggested one-
year mortality rate of 5% is estimated in patients who re-
ceive NT and eventually a pancreatoduodenectomy
(Group 2) [16, 17]. We aim to evaluate if this improve-
ment is achievable in a randomized controlled trial. To
show a reduction in one-year mortality rate from 25 to
5% in a two-armed, parallel-group design with alpha
(significance level) 0.05 and beta (power) of 0.79, a sam-
ple of 34 patients per group is needed.
An estimated one-third of the NT group will not reach
resection and thus not be available for evaluation with
regard to the primary endpoint. Furthermore, we esti-
mate that two patients per study group will have their
scheduled surgery aborted because of unexpected intra-
operative findings. To correct for these patients, a 3:2
randomization is designed, with 36 patients randomized
to SF (Group 1) and 54 patients to NT (Group 2), yield-
ing a total of 90 patients.
Handling cross-over, drop-outs and exclusion
Post-randomisation exclusion is to be avoided at “all
costs”. While patients are offered to withdraw without
giving any reason, this is not considered very likely as
both groups provide standard treatment of today, albeit
at reversed sequence for some (Group 2). Patients who
for some reason cannot fulfil neoadjuvant chemotherapy
(Group 2) but are still considered candidates for resec-
tion will be offered resection according to standard cri-
teria. The reasons for this might be:
 Inability to achieve adequate reduction of bilirubin
levels by drainage within 4 weeks
 Massive adverse reactions to first cycle chemotherapy
These patients are considered cross-over provided no
single cycle was completed, but remain under analysis
by intention-to-treat. They are not excluded from the trial.
Patients who suffer other incidents post-randomisation
but prior to any treatment are still analysed under
intention-to-treat.
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Treatment
Chemotherapy
Neoadjuvant group (Group 2) Neoadjuvant chemo-
therapy consists of 4 cycles (2 months) of FOLFIRINOX
(oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin
400 mg/m2, and 5-fluorouracil (400 mg/m2 bolus then
2400 mg/m2 over 46 h)) [18, 19]. Patients who undergo
surgical resection will receive adjuvant chemotherapy
with 4 cycles (4 months) Gemicitabine 1000 mg/m2 over
30 min at day 1, 8, 15 of each 28-day cycle and capecita-
bine 830 mg/m2 ×2 daily for 3 weeks and one week rest
of each 28-day cycle [27]. Adjuvant chemotherapy must
be started within 12 weeks after resection [28]. Dose re-
duction or dose delays are acted upon according to local
clinical practice at each centre.
Surgery-first group (Group 1) Following pancreatic re-
section, all patients receive adjuvant chemotherapy with
6 cycles (6 months) Gemicitabine 1000 mg/m2 over
30 min at day 1, 8, 15 of each 28-day cycle and capecita-
bine 830 mg/m2 ×2 daily for 3 weeks and one week rest of
each 28-day cycle [27]. Adjuvant chemotherapy must be
started within 12 weeks after resection [28].
Side effects of chemotherapy are graded by the
“Common Terminology Criteria for Adverse Events”
version 4 https://evs.nci.nih.gov/ftp1/CTCAE/About.html.
Grade 3–5 are reported. At each study visit, laboratory
parameters are determined for dose adjustments. Dose
reduction or dose delays are acted upon according to local
clinical practice at each centre.
Surgery
Surgery is scheduled within 4 weeks in the control arm,
and also within 4 weeks after the last neoadjuvant infusion
in the treatment arm. Resection of the pancreatic head will
be performed as a standard or pylorus-preserving pancrea-
toduodenectomy with standard lymphadenectomy [29].
The reconstruction is done by a retrocolic end-to-side
pancreatico-jejunostomy and an end-to-side hepatico-
jejunostomy. In addition, an end-to-side duodeno- or gas-
trojejunostomy is performed on a jejunal alpha-loop.
Otherwise, each centre may use its standard perioperative
management for pancreatoduodenectomies. Surgical mor-
bidity is assessed by the Dindo/Clavien classification [21,
30]. Pancreatic fistulas, biliary leakages, delayed gastric
emptying and postoperative haemorrhage are reported
according to the definitions of the ISGPS [22–25].
Pathology examination
The resection specimen will be evaluated according to a
detailed standardized pathology examination protocol
[31, 32]. At the discretion of the local team, the anterior
and posterior surfaces of the pancreas, as well as the su-
perior mesenteric vein groove and surface towards the
superior mesenteric artery may be inked by the surgeon
according to an agreed colour code. The histopatho-
logical response of the tumor to the neoadjuvant treat-
ment will be assessed according to an established
tumour regression grading system [33].
Follow-up
Follow-up is based on physical examination, blood sam-
ples (hemoglobim, white blood cell count, differential
blood count, platelets, creatinin, bilirubin, aspartate ami-
notransferase, alanine aminotransferase, lactate dehydro-
genase, gamma-glutamyl transpeptidase, prothrombin
time, albumin, sodium, potassium, CA19–9 and carci-
noembryonic antigen) and CT scans of chest and abdo-
men at 6, 9, 12, 15 months after surgery and every six
months thereafter until disease recurrence or, in patients
without relapse, at 5-years following surgery. Any newly
appearing lesion with histological documentation of can-
cer defines recurrent disease. Also, any newly appearing
lesion(s) suspicious for malignancy without histological
documentation but increasing in size upon repeated
follow-up exams, especially in the context of progressive
symptoms (pain, weight loss) or increasing tumor
marker (CA 19–9) levels, are considered recurrent dis-
ease, either distant, regionally or in the former surgical
bed. The date of recurrence is defined as the date of
radiological or histological evidence of relapse. The
study ends when the last randomized patient has been
followed for 5 years after surgery.
Quality of life
Quality of life will be assessed by the QLQ-30 of the
European Organization for Research and Treatment of
Cancer at study inclusion, before randomization, before
surgery in the neoadjuvant arm, and at 4 weeks after
surgery, as well as at any follow-up visit.
Translational research
Blood samples and tumour tissue will be stored to en-
able further translational research.
Safety
Suspected Unexpected Serious Adverse Reactions will be
reported to the Competent Authority and Ethics Commit-
tee according to national regulation. The sponsor will en-
sure that all relevant information about suspected serious
unexpected adverse reactions that are fatal or life-
threatening is recorded and reported as soon as possible to
the Competent Authority and Ethics Committee after
knowledge by the sponsor of such a case, and that relevant
follow-up information is subsequently communicated. All
other suspected serious unexpected adverse reactions will
be reported to the Competent Authority concerned and to
the Ethics Committee concerned as soon as of first
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knowledge by the sponsor. A Data Monitoring Committee
will be established with specialists in gastroenterological sur-
gery and medical oncology. The study will be closed if 50%
or more of the patients randomized to NT do not receive
the planned surgery or if the reason for not receiving surgery
is reduced performance status or side effects due to neoadju-
vant chemotherapy in more than 30% of the randomized
patients.
Ethics
The study protocol was approved by the Regional Com-
mittee for Medical and Health Research Ethics (2015/
610/REK Nord) and The Norwegian Medicines Agency
(15/05308–8). Patients must provide written consent be-
fore entering the trial. All data will be handled with
strict confidentiality, and study reports or presentations
will maintain the anonymity of patients.
Discussion
The NorPACT-1 study investigates the benefit of NT to
the standard treatment (surgery + adjuvant chemotherapy)
for resectable cancer of the pancreatic head as a means of
avoiding early mortality (within one year) in resected pa-
tients. The study results will show which of the two treat-
ment strategies is superior with respect to survival and
quality of life in patients undergoing surgery for resectable
pancreatic cancer. Non-randomized data have provided
some support for NT, but these observations may be
biased by patient selection bias. Hence, only a randomized
comparison can objectively show benefit of one strategy
over the other. The main rationale for NT in this patient
group is twofold. First, upfront chemotherapy enable early
treatment of micrometastases. Second, postoperative com-
plications often preclude initiation or completion of adju-
vant chemotherapy and thereby annul the benefits of
multimodal treatment. By delivering NT prior to surgical
resection, the chance of receiving both modalities is in-
creased. Furthermore, NT is likely to result in improved
patient selection for surgery, as individuals with rapidly
progressive disease under NT can be spared from major
surgery, which is unlikely to be beneficial and associated
with significant morbidity risk. Systemic therapy in
NorPACT-1 is given with chemotherapy combinations
that have shown promising results in two recent random-
ized controlled trials [19, 27]. The multicentre design with
participation of the five centres that perform pancreatic
surgery in Norway ensures that any eligible patient has
the opportunity to participate in the clinical trial at the
centre closest to his/her home. Bolt-on to the proposed
study is a translational research program that aims at
identifying factors that are predictive of response to NT,
the risk of distant cancer spread and patient outcome.
These potential biomarkers will allow better patient selec-
tion for surgery and/or NT.
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